Corrigendum: Advanced NSCLC patients with EGFR T790M harbouring TP53 R273C or KRAS G12V cannot benefit from osimertinib based on a clinical multicentre study by tissue and liquid biopsy

Corrigendum: Advanced NSCLC patients with EGFR T790M harbouring TP53 R273C or KRAS G12V cannot benefit from osimertinib based on a clinical multicentre study by tissue and liquid biopsy

[This corrects the article DOI: 10.3389/fonc.2021.621992.].

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Frontiers in oncology 2023-06, Vol.13, p.1236311-1236311
Hauptverfasser: Fu, Yulong, Wang, Anqi, Zhou, Jieqi, Feng, Wei, Shi, Minhua, Xu, Xiao, Zhao, Hongqing, Cai, Liming, Feng, Jian, Lv, Xuedong, Zhang, Xiaodong, Xu, Wenjing, Zhang, Zhengrong, Ma, Guoer, Wang, Jian, Zhou, Tong, Zhao, Dahai, Fang, Haohui, Liu, Zeyi, Huang, Jian-An
Format: Artikel
Sprache:eng
Schlagworte:
drug resistance
epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI)
gene sequencing
liquid biopsy
non-small cell lung cancer
Oncology
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:[This corrects the article DOI: 10.3389/fonc.2021.621992.].
ISSN:2234-943X
2234-943X
DOI:10.3389/fonc.2023.1236311